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Previous research has indicated that cancer patients with high
grades of tumour-infiltrating lymphocytes (TILs) have a better
prognosis for many tumours, including gastric cancer (MacCarty
and Mahle 1921, Black et al, 1956; Miwa et al, 1984). 
A number of recent studies have also demonstrated that tumour-
specific cytotoxic T cells (CTLs) are present in TILs from patients
with tumours of various types, including melanoma (Itoh et al,
1986; Topalian et al, 1989), renal cancer (Schenidel et al, 1993),
ovarian cancer (Ionaaides et al, 1993), sarcoma (Slovin et al,
1986), squamous cell cancer of the head and neck (Yasumura et al,
1994), and gastric cancer (Ikeda et al, 1996). About 35 years ago,
we found an increase of TILs in resected gastric cancer specimens
after intratumoral injection of BCG 1 to 2 weeks before operation.
Subsequently, we have performed preoperative intratumoral injec-
tion of various biological response modifiers (BRMs), such as
BCG-CWS, Nocardia rubra-CWS, OK-432, PSK, and IL-2, in
gastric cancer patients (Miwa et al, 1984; Moriyasu et al, 1985;
Akura et al, 1986). Any of these BRMs injected 1 to 2 weeks
before operation trigger an increase of TILs in the resected
tumours of two-thirds of the patients. Preliminary study on pre-
operative intratumoral injection of OK-432 (OK-432 it) was
performed, because OK-432 has been a commercially available
BRM which has been widely used in Japan for over 20 years. TILs
were moderately positive in 40% and markedly positive in 33% of
the patients with preoperative OK-432 it compared with only 31%
and 0%, respectively, in the control group without OK-432 it
(Miwa et al, 1984). It remains of great interest to determine
whether TILs induced by OK-432 it can improve the postoperative
prognosis of gastric cancer patients. 
Although there has been remarkable development of
gastroscopy for the early detection of gastric cancer as well as
improvement of surgical techniques during the last 3 decades, the
5-year survival rate of advanced gastric cancer patients under-
going curative resection has remained at 20 to 49% for stage III
and 5 to 15% for stage IV (The Japanese Gastric Cancer Study
Group 1981; Siewert et al, 1993). Nevertheless, the majority of
such patients die of a recurrence based on microscopic residual
tumours. In order to eradicate those microscopical residual
tumours postoperative adjuvant chemotherapy with intravenous
mitomycin C (MMC) and oral 5-FU or 5-FU derivatives like
tegafur has been routinely performed for advanced gastric cancer
patients in Japan for the last 20 years (Inokuchi et al, 1984;
Maehara et al, 1991; Nakazato, 1994). Subsequently, systemic
nonspecific immunotherapy with OK-432 has been widely
combined with adjuvant chemotherapy, because immunotherapy is
generally more effective when the residual tumour mass is quite
small (Arinaga et al, 1992). 
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doi: 10.1054/ bjoc.2000.1599, available online at http://www.idealibrary.com on  http://www.bjcancer.comOn the basis of such adjuvant chemoimmunotherapy for gastric
cancer patients, we conducted a multi-institutional randomized
control trial of adjuvant chemoimmunotherapy consisting of MMC,
tegafur, intradermal injection of OK-432 with or without preoper-
ative OK-432 it in gastric cancer patients between June 1985 and
December 1986. 
The present article is the final report. According to the UICC:
TNM classification of gastric cancers (4th edition), we found that
OK-432 it significantly improved the 10-year survival of gastric
cancer patients with stage IIIA+IIIB, positive TILs, pN2 lymph
node metastasis. In particular, OK-432 it was useful for patients
with positive TILs and pN(+) when used in combination with
adjuvant chemoimmunotherapy. 
MATERIALS AND METHODS 
Stratification and randomization of patients 
The procedures have been described previously (Tanaka et al,
1994). Briefly, from April 1985 to December 1986, patients with
gastric cancer determined endoscopically to be advanced but cur-
atively resectable were randomly enrolled into either the OK- 432
it group or the control group after kindly informed consent. 
Protocol and postoperative treatment 
Patients in the OK-432 it group had endoscopic injection of OK-
432 (10 KE 5 ml21 saline) into approximately 10 sites in the
tumour using NM-1K needles (Olympus Co, Japan) at 7 to 14 days
before surgery. Patients in the control group were not treated
before the operation. All patients received identical postoperative
chemoimmunotherapy. MMC (0.4 mg kg21) was injected intra-
venously immediately after the operation. Oral tegafur (600 mg
day21) and intradermal injection of OK-432 (5 KE 2 weeks21)
were given from postoperative day 14 for up to 1 year later as
maintenance therapy. 
OK-432 
OK-432 is a penicillin-treated lyophilized powder of the
avirulent Su strain of human Group A Streptococcus pyogenes
(Chugai Pharmaceutical, Tokyo, Japan). The Klinische Einheit
(KE) unit is used to express the strength of the preparation, with
1 KE of OK-432 being equivalent to 0.1 mg of dried strepto-
coccal cells. 
Tegafur 
Tegafur (1-(2-tetra hydrouranyl)-5-fluorouracil, MW:200) is a
prodrug that is slowly metabolized to 5-FU by microsomal
cytochrome p450, which is mainly found in the liver, and soluble
enzymes. Tegafur has comparable activity with that of 5-FU. 
Histopathological examination 
To assess treatment efficacy, haematoxylin-eosin stained resected
specimens of the main tumour and dissected lymph nodes were
examined independently by 3 pathologists, and the mode evalua-
tions was determined. 
TILs were graded as absent, mild, moderate, or marked, with
absent or mild TILs being classified as negative and moderate or
marked TILs as positive. A total of 2829 dissected lymph nodes
was examined for metastasis. The pattern of nodal metastasis was
classified as minor-solitary, minor-multiple, major-solitary and
major-multiple. The classifications of ‘minor’ or ‘major’ was
based on the size of metastatic foci, i.e., under or over 0.2 mm in
diameter, while ‘solitary’ or ‘multiple’ was based on the number
of metastatic foci on each node. 
Statistical analysis 
The chi-squared test was used to evaluate the clinical characterist-
ics. The survival rate and disease-free survival rate were estimated
by the Kaplan-Meier method, and statistical significance was eval-
uated by the log-rank test. The comparison of histological findings
was performed with Student’s t-test. Cox’s proportional hazards
regression was used to assess the impact of treatment after adjust-
ment for other characteristics. Statistical analysis, including multi-
variate analysis, was performed with Statistical Analysis System
(SAS) software. 
RESULTS 
Clinical and pathological characteristics 
Table 1 compares the two groups with respect to sex, age,
macroscopic stage, lymph node metastasis, lymph node dissec-
tion, operative curability and microscopic findings due to post-
operative evaluation. Some cases with distant metastasis were
enrolled for difficulty of pre-operative staging due to micro foci
of liver or peritoneum. Excluding age, there were no significant
differences between the two groups, and the age difference had
no significant influence on survival according to multivariate
analysis and adjusted analysis by age. These were no differ-
ences in background between the 39 patients in the OK-432 it
group and the 32 patients in the control group with stage
IIIA+IIIB. 
The grade of TILs in the OK-432 it group were 4 cases in
absent, 104 cases in mild, and 51 cases in moderate or marked and
in the control group, 13, 100 and 38, respectively. There was a
significant difference in the grade of TILs between two groups
(P = 0.038). 
There were no significant differences between two arms in the
total doses of adjuvant chemoimmunotherapy. 55% of OK-432 it
group and 58% of control group were administrated more than
75% of the planned doses. 
Survival and disease-free survival 
At the end of December 1996, all subjects had been followed up
for 10 years. 187 of the 370 eligible patients had died. 93 out of
187 patients died of cancer or other disease in the OK-432 it
group and 94 out of 183 died in the control group. The survival
curves for the two groups are shown in Figure 1A. The overall 5-
year survival rate was 58.7% for the OK-432 it group and 56.8%
for the control group, while the 10-year survival rate was 49.5%
and 48.2%, respectively (P = 0.5085). The disease-free survival
rate of curatively resected patients was also not different for the
two groups throughout the follow-up period (P = 0.2005) (Figure
1B). 
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Table 1 Clinical and pathologic characteristics
Enrolled all patients (n = 370) Histological stage IIIA+IIIB (n = 71)
Characteristics OK-432 it  Control  Chi square OK-432 it  Control  Chi square 
(n = 187) (n = 183) (n = 39) (n = 32)
Sex 0.002 0.330 
Male 123 120 NS 23 21 NS 
Female 64 63 16 11 
Age (yrs) 15.996 2.837 
Up to 39 11 1 P < 0.01 2 0 NS 
40–49 27 19 3 5 
50–59 61 48 14 10 
60–69 63 74 15 12 
Over 70 25 41 5 5 
Depth of invasion (histological) 2.579 1.886 
pT1 42 51 NS 0 0 NS 
pT2 88 78 11 13 
pT3 40 38 27 19 
pT4 14 11 1 0 
Unknown 3 5 0 0 
Nodal involvement (histological) 4.120 1.525 
pN0 76 79 NS 1 0 NS 
pN1 67 49 18 12 
pN2 27 29 20 20 
pM1 11 17 
Unknown 6 9 
Distant metastasis 0.484 
M0 157 150 39 32 NS 
M1 29 32
Pathological stage 1.921 0.01 
IA 35 40 NS – – NS 
IB 39 38
II 38 33 
IIIA 30 25 30 25 
IIIB 9 7 9 7 
IV 31 37 
Unknown 6 8 
Operation method 1.715 0.104 
Total 42 40 NS 12 11 NS 
Extended gastrectomy 141 136 27 21 
Non-resectable 4 7 0 0 
NS: not significant. According to the UICC classification (4th edition). 
Incidence and site of recurrence 
The sites of recurrence were identified during follow-up in 71
of the 370 patients who underwent curative resection. All
types of recurrence were reduced in the OK-432 it group
compared with the control group and both regional lymph
nodal and haematogeneous recurrence were markedly reduced
(Table 2). 
Effect of stage, TILs grade, and extent of lymph node
metastasis 
OK-432 it significantly improved the survival rate of stage
IIIA+IIIB patients (Figure 2). Among the patients who were nega-
tive for TILs, there was no difference in survival between the OK-
432 it and the control groups. However, among TILs-positive
patients, the OK-432 it group showed a 30% higher survival rate
than the control group from the 2nd year after surgery (P =
0.0149). The survival rate of patients with pN2 was also higher
in the OK-432 it group than in the control group (P = 0.0552)
(Figure 3). 
Relationship among survival rate, TILs grade, and
extent of lymph node metastasis (Figure 4) 
Among TILs-positive patients who had lymph node metastasis,
OK-432 it was found to be most effective in improving the
survival rate (P < 0.001). 
Relationship between TILs grade and the frequency of
metastatic lymph nodes 
There was no difference between the OK-432 it group and the
control group in the frequency of patients having metastatic lymph
nodes. 
Although, the number of dissected lymph nodes per patient was
similar in both groups, irrespective of the presence or absence of
OK-432 it or TILs. However, a significant difference was found in
the number of metastatic lymph nodes per patient. The ratio of
metastatic nodes were markedly lower in the OK-432 it group with
positive TILs than in the control group with positive TILs
(Table 3). Only in the OK-432 it patients with positive TILs did
the number of metastatic lymph nodes per patient decreasesignificantly in the regional through the distant node groups. The
number of metastatic lymph nodes per patient in the regional node
group was 2.11 in the OK-432 it patients with positive TILs, 4.47
in the OK-432 it patients with negative TILs, 4.62 in the control
patients with TILs, and 4.72 in the control patients without TILs. 
Relationship between OK-432 it and pattern of lymph
node metastasis (Table 4) 
The minor metastatic foci was smaller in the OK-432 it group than
in the control group, particularly in the distant nodes from the
main tumour than in the regional (perigastric and periarterial)
nodes, suggesting that minor metastatic foci may be eliminated by
OK-432 it. 
Multivariate analysis of prognostic factors (Table 5) 
8 variable factors, which were the extension of the primary tumour
(pT), the extent of regional lymph node metastasis (pN), sex, age,
venous invasion, lymphatic invasion and TILs, were selected by
Cox’s regression analysis. In the control group, pN was the most
important prognostic factor. On the other hand, in the OK-432 it
group, TILs was a significant factor rather than pN. 
DISCUSSION 
The mortality rate from gastric cancer has been decreasing world-
wide (Howson et al, 1986; Stat Bite, 1998), however, gastric cancer
remains one of the major causes of death in Japan. Despite the
progress of endoscopic diagnosis and surgical procedures in the last
3 decades, the survival rate after curative resection of advanced
gastric cancer has remained low (The Japanese Gastric Cancer
Study Group, 1981; Siewert et al, 1993). There has been and
still is no established adjuvant chemotherapy for gastric cancer.
Accordingly, various type of adjuvant chemotherapy and/or adjuv-
ant chemoimmunotherapy have been performed to improve the
survival rate after operation for advanced gastric cancer. In those
days of protocol planning, administration of intravenous MMC and
oral tegafur (fluorouracil) had been the standard adjuvant
chemotherapy for postoperative gastric cancer patients in Japan.
Tegafur (Grem, 1996) is orally administered as a prodrug of 5-FU.
Phase II trials in various solid tumours have indicated that tegafur
has an activity equal to that of 5-FU. Adjuvant chemoim-
munotherapy has been extensively performed by systemic adminis-
tration of OK-432 for a variety of malignancies (Watanabe and lwa,
1984; Cervical Cancer Immunotherapy Group, 1987; Arinaga et al,
1997). OK-432 is an immunomodulatory agent prepared from an
avirulent human strain of Streptococcus pyogenes. It has been
shown to induce various cytokines, especially Th1 cytokines (Saito
et al, 1982; Yamamoto et al, 1986; Yang et al, 1992) and to upregu-
late both perforin (Kataoka et al, 1991) and Fas ligand expression
(Toda et al, 1996; Sato et al, 1997) of immune cells. In accordance
with these findings, OK-432 is also known to enhance or activate
the cytotoxic activity of various effector cells (Ishii et al, 1976;
Uchida and Micksha, 1983), which may be responsible for its ther-
apeutic effect. The augmentation of perforin (Kataoka et al, 1991),
induction of IL-2 and IFN-g, and the upregulation of Fas ligand
(Toda et al, 1996; Sato et al, 1997) by OK-432 may play a major
role in promoting anti-tumour necrotic and apoptotic effects of
immune cells like NK cells, LAK cells, CTL (Kagii et al, 1994;
Lowin et al, 1994; Lin et al, 1995; Frost et al, 1997), and TILs.
These such biological activity of OK-432 are thought to occur at
the tumour site in the case of intratumoral injection of OK-432. In
our previous studies (Gotoh et al, 1991). TILs induced by OK-432
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Table 2 Incidence and site of recurrence of curatively resected cases 
OK-432 i.t (%)  Control (%)  
(n = 152) (n = 147)
No. of recurrent cases 31  (20.4) 40  (27.2) 
Recurrence site 
Peritoneum 20 (13.2) 22  (15.0) 
Local 2 3 
Vesseral type* 15 27 
Lymph node 4 (3.6) 9  (9.3) 
Haematogenic 11 (9.8) 18 (12.2) 
Liver 6 10 
Lung 1 4 
Bone 4 3 
Brain 0 1 
Included multi-focal recurrence sites. *P = 0.034 by x2 test control vs.
OK – 432 it. 
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Figure 1(A) Overall survival curves for gastric cancer patients with and
without preoperative intratumoral injection of OK-432. (B) Disease-free
survival curves for gastric cancer patients with and without preoperative
intratumoral injection of OK-432 it showed augmented NK- and LAK activity, whereas TILs from
patients without OK-432 it had no antitumor activity. Considerable
destruction of tumour cells was also found in tumour specimens
from patients with OK-432 it. Recently, Khalili et al (1998)
reported that in ovarian cancer patients the spontaneous production
of IL-10 and TNF-a were higher in TILs than in peripheral blood
mononuclear cells, and the anti-CD3-induced IL-12 production was
dramatically lower in TILs. These biased Th2-dominant cytokines
might contribute to the anergic T cell function against tumour cells
in TILs. IL-10 is also produced by various human solid tumours
and could serve to blunt a natural or induced antitumor immune
response in the tumour site (Maguri et al, 1997). Lopez et al (1998)
also reported that TILs from breast cancer were defective both in
proliferate response and IL-2 receptor mRNA expression but
recovered when incubated in the presence of recombinant IL-2.
These findings support that anergic TILs in gastric cancer patients
may recover the antitumor activity in the presence of Th1-dominant
cytokines including IL-2 and IFN-g induced by OK-432 it. When
dissected regional lymph nodes from OK-432 it patients were
stained with an anti-OK-432 antibody, macrophages containing
OK-432 particles were found in all the dissected nodes from peri-
gastric to para-aortic (data not shown). We previously reported that
lymph nodes and TILs from patients with OK-432 it also demon-
strated NK- and LAK activity, but no antitumor activity was seen in
the nodes from patients without OK-432 it (Gotoh K et al, 1991). In
this study, we reconfirmed that the grade of TILs was significantly
increased in the OK-432 it group. The antitumor activity of TILs
and lymph nodes activated by OK-432 it may be responsible for
improving the 10-year survival rate of patients with stage IIIA+IIIB
with positive TILs, and with both positive TILs and positive node
metastasis in the group of OK-432 it. Our follow-up study of recur-
rence showed that regional lymph node metastasis and haematoge-
neous metastasis were significantly lower in the group with
OK-432 it. The number of metastatic lymph nodes was markedly
decreased in the OK-432 it patients with positive TILs. In our
multivariate analysis of 8 prognostic factors, pN was the most
important prognostic factor in the control group but it was not
significant in the OK-432 it group. The number of dissected lymph
nodes with micrometastasis was decreased in the OK-432 it group.
Moreover, the number of metastatic lymph nodes per patient was
significantly decreased in the OK-432 it patients with positive
TILs. These findings suggest the possibility of elimination of
micrometastatic foci in regional lymph nodes by OK-432 it.
Because we previously reported that injected OK-432 distributed in
the regional lymph nodes, lymphocytes of TILs or regional lymph
nodes co-cultured with OK-432 produced TNF-a IFN-g and other
cytokines within 4 to 12 hours and obtained cytotoxicity for tumour
cells. And also multivariated analysis suggests that the younger
patients who have not so impaired immune responsibility were
more suitable for this therapy. 
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Figure 2 Survival curves for gastric cancer patients with and without preoperative intratumoral injection of OK-432 according to clinical stage 
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Table 3 Relationship between grade of TILs and grade of lymph node metastasis 
Metastatic incidence by case (%) Metastatic incidence by node (%) 
TI Ls Metastatic cases/Whole cases Metastatic nodes/Whole nodes 
OK-432 i.t. Control OK-432 i.t. Control 
No–mild 57.5 57.7 21.7 21.0 
Moderate–marked 58.8 56.8 9.4 22.9 
OK-432 i.t. vs control of metastatic incidence by node: P < 0.001. 
Table 4 Morphologic pattern of metastatic foci on lymph nodes 
OK-432 i.t. Control 
Minor Major Minor Major 
Solitary Multiple Solitary Multiple Solitary Multiple Solitary Multiple 
Regional 
Perigastric 67 10 46 141 103 11 43 158 
Periarterial 20 2 12 39 24 4 21 29 
Distal 
Para-aortic 1 0 4 14 3 0 0 5 
Total 88 12 62 194 130 15 64 192 
The ratio of minor type in OK-432 is significantly reduced than that in control (P = 0.018). 
Figure 3 Relationship between grade of extent of lymph node metastasis and survival rate for gastric cancer patients with and without preoperative
intratumoral injection of OK-432 
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Table 5 Multivariate analysis for survival risk 
Control OK-432 it 
Variables Wald Chi-Square P value Wald  Chi-Square P value
§
pN 4.4967 0.034 1.2152 0,270 
(1.335: 1.022–1.743) (1.228:0.852–1.779) 
pT 4.0119 0.045 5.0619 0.025 
(1.431: 1.008–2.032) (1.683: 1.069–2.648) 
v 3.5587 0.059 0.0126 0.911 
(1.289:0.990–1.679) (0.980: 0.694–1.386) 
ly 1.7196 0.189 4.0778 0.044 
(1.209: 0.910–1.606) (1.363: 1.0.09–1.841) 
INF 0.8629 0.353 0.0628 0.802 
(1.235: 0.791–1.928) (0.947:0.621–1.445) 
TIL 0.2830 0.595 11.083 0.001 
(1.181: 0.640–2.178) (0.329: 0.171–0.633) 
sex 0.2761 0.599 0.003 0.953 
(0.871: 0.520–1.459) (0.983: 0.557–1.735) 
age 0.0030 0.956 5.196 0.023 
(0.992: 0.738–1.333) (1.347: 1.043–1.739) 
v: the degree of venous invasion; ly: the degree of lymphatic invasion; INF: the pattern of infiltrating growth into the
surrounding tissue. These classifications were according to Japanese Classification of Gastric Carcinoma (First
English Edition). 
Figure 4 Relationship among survival rate, TILs grade, and extent of lymph node metastasis
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Advanced gastric cancer patients who are positive for TILs after
OK-432 it should be considered as responders to OK-432, to
whom adjuvant immunotherapy with intradermal injection of OK-
432 should be continued in order to suppress recurrence over the
long term, particularly in stage IIIA+IIIB. 
The eradication of micro-metastasis is a most important strategy
to improve the prognosis of cancer patients. Our study shows that
preoperative intratumoral injection of OK-432 will be a more
promising neoadjuvant immunotherapy for advanced gastric
cancer patients.
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